Prostate biopsy techniques and indications: When, where, and how?

Seminars in Urologic Oncology

Volumn 20, Issue 1, 2002, Pages 18-31

  Scherr, Douglas S ^a   Eastham, James ^a   Ohori, Makoto ^a   Scardino, Peter T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Prostate biopsy; Prostate cancer; Transrectal ultrasound

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC PROCEDURE; HUMAN; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0036171382     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.30395     Document Type: Review

References (128)

1. Transurethral and transrectal ultrasonic scanning in urology
2. Prostate and seminal vesicles
3. Clinical evaluation of inside echo patterns in gray scale prostatic echography
4. Prostatic evaluation by transrectal sonography with histopathologic evaluation: The echopenic appearance of early carcinoma
5. The appearance of prostate cancer on transrectal ultrasonography: Correlation of imaging and pathological examinations
6. Detection of microscopic extracapsular extension prior to radical prostatectomy for clinically localized prostate cancer
7. Urologic ultrasonography
8. Comparison of the pathologic features and DNA ploidy value of prostate cancers detectable by sonography and by palpation
9. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: A randomized controlled study
10. Morbidity with contemporary prostate biopsy
11. Determinants of complications after multiple transrectal core biopsies of the prostate
12. Infection after transrectal core biopsies of the prostate-risk factors and antibiotic prophylaxis
13. Morbidity of ultrasound guided transrectal core biopsy of the prostate without antibiotic therapy
14. Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy
15. Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications?
16. Prevention of bacterial endocarditis: Recommendations by the American Heart Association
17. Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer
18. Effect of local anesthetics on patient recovery after transrectal biopsy
19. Periprostatic nerve blockade for transrectal ultrasound guided biopsy of the prostate: A randomized, double-blind, placebo controlled study
20. Ultrasound of the prostate and biopsy
21. PSA as the initial test in prostate carcinoma screening: Results of the third year
22. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate
23. Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer
24. The influence of prostate size on cancer detection
25. Outcome of sextant biopsy according to gland volume
26. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels
27. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values
28. Repeat prostate needle biopsy: Who needs it?
29. Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer
30. Role of PSA and its indices in determining the need for repeat prostate biopsies
31. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection
32. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate
33. Comparison of sextant to 5-region biopsy technique using a 3-D computer simulation of actual prostate specimens
34. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer
35. Three-dimensional computersimulated prostate models: Lateral prostate biopsies increase the detection rate of prostate cancer
36. Comparison of prostate biopsy schemes by computer simulation
37. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies
38. Importance of posterolateral needle biopsies in the detection of prostate cancer
39. Prostate-specific antigen: Current status
40. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer
41. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men
42. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
43. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: Lack of prediction of tumor significance for men with nonpalpable prostate cancer
44. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy
45. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: A report of 454 cases
46. A pre-operative nomogram predicting positive surgical margins after radical prostatectomy
47. Development of an improved nomogram including features of systematic biopsies to predict organ confined (OC) prostate cancer in patients undergoing radical prostatectomy (RP)
48. Utilizing predictors of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials
49. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
50. The role of perineural space invasion in the local spread of prostatic adenocarcinoma
51. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate
52. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
53. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer
54. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: Perineural invasion lacks significance on multivariate analysis
55. The pathological interpretation and significance of prostate needle biopsy findings: Implications and current controversies
56. Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen
57. Improved prediction of extracapsular extension (ECE) using individually labelled systematic biopsies (SYSBX) in patients undergoing radical prostatectomy (RP)
58. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings
59. Discrepancies between Gleason scores of needle biopsy and radical prostatectomy specimens
60. Prediction of organconfined prostate cancer in a contemporary clinical stage TlC referral series: The new challenge
61. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
62. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
63. Predicting the risk of lymph node involvement using pre-treatment prostatic specific antigen and Gleason score in men with clinically localized prostate cancer
64. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer
65. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer
66. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy
67. Prediction of prostate carcinoma stage by quantitative biopsy pathology
68. Features of cancer in systematic biopsies (SYSBX) improve the prediction of clinical indolent prostate cancer (PCA) in patients undergoing radical prostatectomy (RP)
69. Age prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer
70. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
71. Diagnosis of prostatic carcinoma: The yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography
72. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
73. Screening for prostatic carcinoma with prostate specific antigen
74. Prostate-specific antigen and other serum markers: Current concepts from the World Health Organization Second International Consultation on Prostate Cancer
75. Longitudinal screening for prostate cancer with prostate-specific antigen
76. A complex between PSA and a 1-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
77. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.5l to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model
78. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
79. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer
80. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenter clinical trial
81. Percent free prostate-specific antigen for first-time prostate biopsy
82. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges
83. Age-specific prostatespecific antigen: A reassessment
84. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer?
85. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen
86. Prostate specific antigen density of the transition zone in the detection of prostate cancer
87. Transition zone prostate specific antigen density: Lack of use in prediction of prostatic carcinoma
88. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease
89. Biological variation of prostate specific antigen levels in serum: An evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients
90. The relationship between prostate cancer and prostatic intraepithelial neoplasia: Critical issue
91. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies
92. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy
93. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens
94. Prostatic intraepithelial neoplasia and prostate-specific antigen
95. Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate
96. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels
97. Significance of prostatic intraepithelial neoplasia on prostate needle biopsy
98. Strategy for repeat biopsy in patients with high grade prostatic intraepithelial neoplasia
99. Clinical management of premalignant lesions of the prostate
100. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: Clinical significance in 33 cases
101. ASAP is a valid diagnosis. Atypical small acinar proliferation
102. The association of benign prostatic hyperplasia and cancer of the prostate
103. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy
104. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer
105. Natural history of progression after PSA elevation following radical prostatectomy
106. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
107. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels
108. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy
109. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy
110. Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins
111. Prostate specific antigen and local recurrence after radical prostatectomy
112. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy
113. Incidence and clinical significance of false-negative sextant biopsies of the prostate
114. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate
115. Results of transition zone biopsy in black and white men with suspected prostate cancer
116. Prostate biopsy protocols: 3D visualization-based evaluation and clinical correlation
117. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer
118. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy
119. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology
120. Prostate cancer sampled on sextant needle biopsy: Significance of cancer on multiple cores from different areas of the prostate
121. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
122. Effect of local anesthesia on patient recovery after transrectal biopsy
123. Transrectal ultrasound guided nerve blockade eases systematic needle biopsy of the prostate
124. Periprostatic local anesthesia before ultrasound guided prostate biopsy
125. Randomized prospective study of intrarectal lidocaine for pain control during transrectal prostate biopsy: The Emory University experience
126. The rectal administration of lidocaine gel and tolerance of transrectal ultrasound guided biopsy of the prostate: A prospectve randomized placebo-controlled study
127. Pain and morbidity of transrectal ultrasound guided prostate biopsy
128. Periprostatic nerve blockade for the transrectal ultrasound guided biopsy of the prostate: A randomized, double-blind, placebo controlled study